Related Experiment Video
Updated: May 28, 2026

Culture Methods to Determine the Limit of Detection and Survival in Transport Media of Campylobacter Jejuni in Human Fecal Specimens
Published on: March 10, 2020
Causes of delay in referral of patients with phenylketonuria to a specialized reference centre in Mexico
M Vela-Amieva1, I Ibarra-González, C Fernández-Lainez
1Laboratorio de Errores Innatos del Metabolismo y Tamiz, Instituto Nacional de Pediatria, Secretaria de Salud, Mexico. dravelaamieva@yahoo.com
Insights
Late referral of phenylketonuria (PKU) patients in Mexico is primarily due to the absence of newborn screening (NBS) for PKU. Improving NBS program function is crucial for timely diagnosis and treatment.
Area of Science:
- Medical Genetics
- Pediatrics
- Public Health
Background:
- Phenylketonuria (PKU) is a genetic disorder requiring early detection and management.
- Delayed diagnosis of PKU can lead to severe neurological complications.
- Effective newborn screening (NBS) programs are vital for identifying infants with PKU.
Purpose of the Study:
- To identify reasons for delayed patient referrals to a reference center for phenylketonuria (PKU).
- To characterize the clinical presentation of PKU patients with delayed diagnosis.
- To evaluate the effectiveness of the newborn screening (NBS) program in Mexico for PKU.
Main Methods:
- Retrospective analysis of 57 PKU patient files over 18 years at the National Institute of Pediatrics, Mexico City.
- Patients categorized into early (Group I, <1 month) and late (Group II, >30 days) referral groups.
- Documentation of time delays and specific causes for late referrals.
Main Results:
- Only 10 out of 57 patients were referred within the first month of life (Group I).
- 47 patients (Group II) were referred late, with causes including lack of routine PKU testing, sampling issues, and administrative failures.
- Absence of PKU testing in the NBS program was a significant factor in late referrals.
Conclusions:
- The primary barrier to timely PKU diagnosis in Mexico is the lack of integrated PKU testing within the NBS program.
- Challenges in NBS program expansion and function in Mexico contribute to delayed patient identification.
- Enhancing the NBS system with PKU testing and quality indicators is essential for prompt PKU management.
Objective:
To expose causes leading to the delayed arrival of phenylketonuria (PKU) patients at a governmental reference centre (RC), and to describe their clinical characteristics. Material and methods PKU files registered during the past 18 years at the National Institute of Pediatrics in Mexico City were evaluated. Patients were classified into two groups according to their age at arrival: Group I (early reference), patients arriving during the first month of life; and Group II (late reference), those who arrived after thirty days of age. Time and causes of delay were documented.
Results:
Of 57 recorded files, 10 were classified in Group I and 47 in Group II. Causes leading to the late arrival of Group II patients were absence of routine newborn screening (NBS), PKU not included in the routine NBS, sampling after the recommended age, false negative result, results without interpretation and/or instructions to follow, delayed notification of results, poor medical criteria of attending physician, difficulties in obtaining confirmatory tests, and administrative failures.
Conclusion:
The main cause of late referral of PKU patients was the absence of PKU testing. As a developing country, Mexico still faces challenges in the proper functioning and expansion of the NBS programme. Most PKU patients arrived at the RC late, presenting with varying degrees of the clinical spectrum. Incorporating PKU testing into the already established Mexican NBS system and adding quality indicators to guarantee proper operation in all NBS phases is necessary to achieve the goal of identifying, referring, diagnosing, and treating patients promptly.
Related Concept Videos
Inborn Errors of Metabolism
Overview of Protein Metabolism
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption